We describe a sensitive and precise gas-chromatographic method, in which cytosine is used as the internal standard, fordeterminationof an antifungal agent,5-fluorocytosine, inserum. The trimethylsilyl derivative of thisdrug iswell separated from the internalstandard and from normal serum constituents. AmphoteriCinB does notinterfere with the determination of 5-fluorocytosine.
Many clinical microbiologists
still use biological assays to estimate various antibiotics in physiological fluids, even though such procedures are inherently less precise, more difficult to control, and subject to greater interferences than are modern chemical assays. The first chemical method for quantitative determination of sulfonamides was introduced in 1939 by Bratton and Marshall (1) and this colorimetric procedure is still widely used to measure these compounds.
Moreover, when an initial hydrolysis step is included, the biologically inactive N-acetyl metabolite of various sulfonamides can also be determined; hence, it is possible to determine whether patients acetylate these drugs slowly methods for the determination of antibiotics have improved greatly in accuracy, precision, sensitivity, and specificity (3, 4) Berkeley, Calif. 94710). The contents of the tubes were mixed on a vortex-type mixer for 30 s and 5 ml of butanol was then added to each tube with a Repipet. The tubes were shaken for 10 mm in an Eberbach shaker at 250 oscillations per minute and centrifuged at 2000 rpm for 10 mm. The butanol layers were aspirated and discarded. One milliliter of phosphate buffer (1 mol/liter, pH 7.9) was added to the aqueous phase to adjust the pH to 7.4, 5 ml of butanol was added with the Repipet, and the contents of the tubes were mixed and extracted as just described. The phases were separated by centrifugation as described above. The butanol layers were transferred to 7-ml screw-capped silylation vials and evaporated under nitrogen in a water bath at 55 #{176}C. Regis Silylation mix, 50 tl, was added to each vial and the contents of the vials were mixed thoroughly on a vortex-type mixer. Twomicroliter samples were injected into the gas chromatograph.
Standard curves were prepared from pooled normal human serum that contained known amounts of 5-fluorocytosine. These serum standards (10, 25, 50, 75, and 100 mg/liter) were prepared by evaporating appropriate amounts of the working solution of 5-fluorocytosine under nitrogen and adding 200 tl of drug-free serum to the residue. OV-17 on 100/120 Gas Chrom Q (Applied Science Labs., Inc., State College, Pa. 16801). Injector port temperature was 250 #{176}C, detector temperature was 300 #{176}C, and oven temperature was programmed from 100 to 240 #{176}C at 16 oC/min. The nitrogen flow rate was 50 ml/min.
Gas Chromatography

Microbiological
Assay for 5-Fluorocytosine Specimens were analyzed for 5-fluorocytosine according to a modification of the bioassay procedure of Block and Bennett (8). In the original procedure standard solutions of the drug, prepared in pooled, normal human serum, were not ultrafiltered through collodion membranes while serum samples obtained from patients treated concurrently with 5-fluorocytosine and amphotericin B were ultrafiltered. In the modified procedure both standard solutions and patient samples were ultrafiltered.
All bioassays for 5-fluorocytosine were performed in the laboratory of Dr. John E. 
Results
When sera from normal individuals were extracted and derivatized according to the procedure we have described, several chromatographic peaks were observed; however, none interfered with either 5-fluorocytosine or cytosine ( Figure 1A) . Normal sera and sera from patients treated with 5-fluorocytosine did not contain endogenous cytosine. The chromatogram presented in Figure lB 3). Seventeen of these samples were prepared by adding various amounts of 5-fluorocytosine to pooled normal sera and eight were obtained from patients receiving both amphotericin B and 5-fluorocytosine. The mean value for the bioassay was 78.5 mg/liter (range, 5.0 to 194.0 mg/liter).
The mean value by the gas chromatographic procedure was 69.4 mg/liter (range, 4.5 to 156.0 mg/liter).
When values obtained by the gas-chromatographic assay were regressed against those obtained with the bioassay, the slope of the linear least-squares line was 0.85, the intercept was 2.7 mg/liter, and the coefficient of correlation was 0.93. Recovery of 5-fluorocytosine from serum was measured in the following way: a solution of 30 tg of the compound in methanol was evaporated and to the residue was added 1 ml of drug-free serum. This sample was extracted as described in the Methods section; however, volume transfers were quantitated.
Discussion
A second (non-extracted) standard was prepared concurrently by evaporating 30 zg of the same compound to dryness, and both sample and standard were derivatized by addition of 50 zl of silylating reagent. Two microliters of each sample were chromatographed.
The peak height of the serum sample was corrected for solvent transfers. Absolute recovery of the drug from serum was calculated by comparing the ratio of corrected peak height of the extracted serum sample to that of the non-extracted standard. The absolute recoveries of 5-fluorocytosine and cytosine determined by this procedure were 30.3% and 30.9%, respectively.
When concentrations of 5-fluorocytosine ranging from 25-150 mg/liter were prepared in pooled normal sera and assayed according to our procedure, the mean recovery of this drug relative to the internal standard was 95.9% (n = 12).
Within-run reproducibility (CV) for our assay was 4.5% at a concentration of 19.9 mg/liter (n = 10). Between-run reproducibility was 7.5% as determined by the use of paired duplicates according to the following formula: SD = V'd2/2n, where d = difference between duplicate pairs. The mean value for this group of samples was 48.1 mg/liter, with a range of 4.1 to 187.8 mg/liter (n = 23).
Twenty-five serum samples were analyzed for 5-fluorocytosine by the microbiological assay and with the gas chromatographic method we have described ( Figure   The incidence of systemic fungal infections has risen progressively with increased use of such drugs as steroids, antibiotics, and immunosuppressants, and as a result of larger numbers of renal-transplant recipients and more prolonged survival of patients with neoplastic diseases (10, 13). Systemic yeast infections are the most frequently encountered of these opportunistic mycoses and the prognosis in such systemic infections is poor, the overall mortality being 75% (14) . In vitro and clinical studies indicate that 5-fluorocytosine is effective in treating infections from sensitive strains of Candida, Torulopsis, and Cryptococcus (15, 17) .
In man, about 90% of the administered dose of 5-fluorocytosine is excreted unchanged in the urine and the remainder appears in the feces (18). Concentrations of this drug in serum are greater in patients with impaired renal function and clearance is prolonged compared to that observed in patients with normal renal function (8, 15, 19) . Toxic effects of 5-fluorocytosine on the bone marrow and liver have been observed more commonly in patients with renal insufficiency treated with usual therapeutic doses of 5-fluorocytosine (19, 20) , which suggests that rational dosage regimens in such patients should be based on measurements of serum concentrations.
Block and Bennett (8) indicate that peak serum concentrations of 5-fluorocytosine as great as 120 mg/liter can be attained without risk of druginduced toxicity. Concentrations of at least 25 mg/liter of serum should be attained during therapy, because many resistant mutants emerge at lower concentrations Treatment of a number of fungal diseases is frequently undertaken with 5-fluorocytosine and amphotericin B, because this combination is synergistic and reduces the development of resistance to 5-fluorocytosine by the infecting organism (6, 7). The usual therapeutic doses of amphotericin B often produce nephrotoxicity;
hence serum concentrations of 5-fluorocytosine should also be monitored in this population to provide safe and effective therapy with the drug.
Although several bioassay procedures for estimating 5-fluorocytosine in serum have been reported, it is difficult to determine their precision because no meaningful information has been published concerning within-or between-run reproducibility (8, 9). It is likely, however, that the precision of these assays is rather limited, because one procedure involves processing all specimens in triplicate and the other in quadruplicate. The within-run coefficient of variation of our assay for 5-fluorocytosine was 4.5% at a concentration of 19.9 mg/liter and the between-run precision (CV) was 7.5 percent. These data suggest that our gas-chromatographic assay has adequate precision to permit determinations on single samples rather than on replicates as required by the bioassays. The relatively good reproducibility of this procedure is due primarily to use of cytosine, a closely related compound, as the internal standard in the assay. When normal human serum was extracted and derivatized according to our procedure without addition of this internal standard, a chromatographic peak with the retention time of the trimethylsilyl derivative of cytosine was not observed. This is consistent with the observations of Bishop et al. (22) , who did not detect free purines or pyrimidines in normal human blood. Our procedure is not interfered with by normal constituents in serum or by amphotericin B, which suggests that it also has requisite specificity for 5-fluorocytosine.
Although chemical methods for analysis of 5-fluorocytosine in biological fluids have not been previously described, several procedures have been reported for the quantitative determination of 5-fluorouracil, an antimetabolite used in cancer chemotheraphy (23, 25) . This drug, a weak acid (pKa = 8.0), can be separated from plasma by various techniques, including dialysis, anion-exchange chromatography, and extraction with a mixture of n-propanol in ether. The trimethylsilyl derivative of 5-fluorouracil has good chromatographic characteristics on OV-1 and SE-30 and the drug can also be derivatized by on-column alkylation with tnmethylanilinium hydroxide. Recently Pantarotto et al. (26) determined by gas chromatography-mass spectrometry that the product of this alkylation is N,Ndimethyl-5-fluorouracil.
The double-extraction procedure we use involves an initial extraction with butanol at pH 3.0 to remove interfering neutral and acidic compounds. 5-Fluorocytosine is not extracted into butanol at this pH. The pH is then adjusted to 7.4 and the drug and internal standard are extracted into butanol. The extraction efficiency of 5-fluorocytosine is only 30.3% and that of the internal standard is 30.9%, which indicates that these compounds have similar partition characteristics.The tnimethylsilyl derivatives of 5-fluorocytosine and cytosine prepared in our assay have excellent chromatographic characteristics and are stable for as long as 24 h if they are protected from moisture. We have also established that 5-fluorocytosine can be alkylated with trimethylanilinium hydroxide; however, this derivative is absorbed to the column and is therefore not suitable for the quantitative determination of the drug. Because of the variation inherent in the bioassay it is difficult to know whether the slope (0.85) that we found for the regression line is statistically different from unity.
Safe and effective treatment with many potent drugs having narrow margins of safety depends in part on measurements of their concentrations in serum (27) . Therapeutic monitoring of antiarrhythmic drugs, anticonvulsants, cardiac glycosides, and the bronchodialator theophylline are increasingly utilized to ensure optimum therapeutic benefit and to avoid drug toxicity. Rapid, specific, accurate, and precise chemical methods are available for these compounds, and it is mandatory that similar techniques be developed for the quantitative determination of antibiotics. 
